Mimetic ERR Agonist for Metabolic Health

SLU-PP-332: An Exercise-Mimetic ERR Agonist for Metabolic Health

by Dr.James Ross 

Disclaimer: All articles and product details provided on this website are intended for educational and informational purposes only. The products listed here are for in-vitro research only. In-vitro studies are conducted outside of living organisms. These products are not intended as medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. The direct or indirect administration of these substances to humans or animals is unequivocally prohibited under applicable law.

Overview

SLU-PP-332 is a next-generation agonist of the estrogen-related receptors (ERRs)—transcriptional “switches” that coordinate cellular energy programs. By preferentially activating ERRα and ERRγ, it turns on the same endurance-training pathways that raise mitochondrial content and capacity, enhance oxidative phosphorylation, and shift fuel use toward fatty-acid oxidation with improved glucose handling.

In preclinical models, SLU-PP-332 increases total energy expenditure and accelerates fat utilization without suppressing appetite, positioning it as a pharmacologic exercise-mimetic under active investigation for fitness enhancement, obesity management, and broader cardiometabolic applications.

ERRs: Master Regulators of Cellular Energy

Although structurally related to estrogen receptors, ERRs do not bind estrogen. Instead, they function as transcription factors that, with coactivators such as PGC-1α, regulate genes for:

• Glucose handling (glycolysis, gluconeogenesis)

• Fatty-acid oxidation and lipid catabolism

• Mitochondrial biogenesis and respiratory capacity

• Oxidative phosphorylation and ATP efficiency

Isoform Highlights

• ERRα (NR3B1): Abundant in skeletal muscle, liver, heart, and brown adipose tissue; governs FAO, mitochondrial programs, insulin sensitivity, and endurance capacity.

• ERRγ (NR3B3): Enriched in cardiac and oxidative skeletal muscle; supports aerobic performance, cardiac output, and mitochondrial function.

• ERRβ (NR3B2): Key in development and pluripotency; emerging roles in differentiation and metabolism.

Given these roles, ERR modulation is being explored for type 2 diabetes, metabolic syndrome, heart failure, muscle atrophy/sarcopenia, and bone health.

Why SLU-PP-332 Is Different

Traditional exercise requires mechanical and neural stimuli to trigger metabolic remodeling. SLU-PP-332 directly activates the same downstream transcriptional circuits, raising energy expenditure and fat oxidation without affecting food intake or drive to be active. Preclinical models suggest:

• Enhanced mitochondrial respiration in myocytes (e.g., C2C12)

• Increased expression of ERR target genes such as Pdk4

• A shift toward oxidative (Type I/IIa) muscle fibers, consistent with endurance adaptations

• Improved running performance and fatigue resistance in mice

• Less fat mass accrual over time despite identical caloric intake

Beyond skeletal muscle, ERR activation in cardiac tissue supports energetic efficiency, and in the brain may bolster neuronal energy homeostasis—areas now being probed for cardiometabolic and neuroprotective potential.

Mechanism of Action: Endurance Biology, Pharmacologically

SLU-PP-332 binds and activates ERRs, stabilizing transcriptional complexes (with PGC-1α and related coactivators) that:

• Upregulate Pdk4 and other nodes governing substrate choice

• Increase mitochondrial content and electron-transport capacity

• Favor fatty-acid oxidation and spare glycogen

• Elevate cellular respiration and ATP availability

Net effect: greater endurance capacity, higher energy flux, and preferential fat utilization—the biochemical signature of aerobic training.

What the Research Suggests (So Far)

• Metabolic health & weight: In diet-induced obese mice, twice-daily SLU-PP-332 for 28 days led to markedly lower fat gain and ~12% total-weight reduction vs. controls, without differences in food intake—consistent with higher energy expenditure and enhanced fat oxidation.

• Performance: Increased oxidative fiber composition and improved run performance/fatigue resistance in C57BL/6J mice.

• Tissue scope: Signals of benefit are being explored in liver (steatosis), heart (energetic efficiency), kidney (mitochondrial function), and brain (neuronal energetics).

Important: Long-term safety and durability in humans remain to be established. Current findings are preclinical or early translational.

Safety, Scope, and Use Cases

Early studies report no significant adverse effects under experimental conditions. Because SLU-PP-332 does not suppress appetite, it differs from classic weight-loss approaches and may be relevant for:

• Obesity/metabolic syndrome: Exercise-mimetic support for fat loss and metabolic flexibility

• Athletes/fitness: Potential aid to endurance and recovery (pending human validation)

• Limited mobility or chronic disease: A pharmacologic route to preserve metabolic health when training is constrained

Nephrology Perspective

Metabolic dysfunction drives kidney injury via lipotoxicity, inflammation, and mitochondrial stress. By enhancing mitochondrial efficiency, fatty-acid oxidation, and insulin sensitivity, SLU-PP-332 could prove renoprotective—particularly in diabetic kidney disease and CKD—if benefits seen preclinically translate clinically.

Complement, Not a Replacement, for Exercise

SLU-PP-332 replicates key metabolic benefits of training but cannot replace the multisystem advantages of physical activity (neuromuscular, vascular, skeletal, cognitive, and psychosocial). Its most realistic role is as a complement to exercise—or a bridge for those unable to train—while comprehensive trials clarify efficacy, dosing, and long-term safety.

Conclusion

SLU-PP-332 exemplifies the “exercise-in-a-pill” concept by pharmacologically activating ERR-driven endurance biology: more mitochondria, better substrate flexibility, higher energy expenditure, and preferential fat use—without appetite suppression. Early data are compelling across performance and metabolic endpoints, and exploratory work in heart, liver, brain, and kidney widens the horizon. Definitive answers now depend on rigorous, peer-reviewed human studies to determine clinical effectiveness, durability, and safety.

Product available for research use only:

References

Billon C, Sitaula S, Banerjee S, Welch R, Elgendy B, Hegazy L, et al. Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity. ACS Chem Biol. 2023;18:756-771. doi: 10.1021/ acschembio.2c00720.

Billon C, Schoepke E, Avdagic A, Chatterjee A, Butler AA, Elgendy B, Walker JK, Burris TP. A Synthetic ERR Agonist Alleviates Metabolic Syndrome. J Pharmacol Exp Ther. 2024 Jan 17;388(2):232-240. doi: 10.1124/jpet.123.001733. PMID: 37739806; PMCID: PMC10801787.

C.-H. Chang, W.-C. Tsai, M.-S. Lin, Y.-H. Hsu, and J.-H. S. Pang, “The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration,” J. Appl. Physiol., vol. 110, no. 3, pp. 774-780, Mar. 2011.

Wang XX, Myakala K, Libby AE, Krawczyk E, Panov J, Jones BA, et al. Estrogen-related receptor agonism reverses mitochondrial dysfunction and inflammation in the aging kidney. Am J Pathology. 2023;193:1969-1987. doi: 10.1016/j. ajpath.2023.07.008.